NCT07042802View on ClinicalTrials.gov

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

December 25, 2027

Study Completion Date

March 25, 2028

Conditions
Ovarian Cancer
Interventions
DRUG

LBL-024 for Injection

LBL-024 Intravenous infusion.

DRUG

Paclitaxel Injection

Paclitaxel Intravenous infusion.

Trial Locations (6)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

110001

The First Hospital of China Medical University, Shenyang

250117

Shandong Cancer Hospital, Jinan

300060

Tianjin Medical University Cancer Institute &Hospital, Tianjin

310022

Zhejiang Cancer Hospital, Hangzhou

650106

Yunnan Cancer Hospital, Kunming

All Listed Sponsors
lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY